Montana is advancing a unique plan to become a hub for experimental medical treatments, allowing biotech companies to sell unapproved drugs to consumers. The state has finalized rules for its expanded "right to try" law, which theoretically permits access to any individual who can pay and provides informed consent, not just those with terminal illnesses. This initiative, driven by longevity enthusiasts, has raised concerns among some experts about the potential risks of selling unproven treatments without FDA oversight. AI
RANK_REASON Policy change by a US state government enabling sale of unapproved drugs. [lever_c_demoted from significant: ic=1 ai=0.1]
Read on MIT Technology Review →
- Aaron S Kesselheim
- Alliance for Longevity Initiatives
- Harvard Medical School
- Ken Bogner
- Matt Kaeberlein
- MIT Technology Review
- Montana
- United States Department of Health and Human Services
- United States Food and Drug Administration
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
